Eventual winner Johnson & Johnson wasn’t Pharmacyclics’ first choice to partner with on ibrutinib, CEO Robert Duggan told FierceBiotech in January, but, as The Wall Street Journal lays out, J&J and its expansive approach to dealmaking won out in the end.

…read more

Source: J&J, Pharmacyclics and the future of Big Pharma dealmaking


0 No comments